Tourmaline Bio Inc. (TRML)
NASDAQ: TRML
· Real-Time Price · USD
47.90
0.03 (0.06%)
At close: Oct 03, 2025, 3:59 PM
47.69
-0.44%
After-hours: Oct 03, 2025, 07:16 PM EDT
0.06% (1D)
| Bid | 47.87 |
| Market Cap | 1.23B |
| Revenue (ttm) | 40K |
| Net Income (ttm) | -88.47M |
| EPS (ttm) | -3.45 |
| PE Ratio (ttm) | -13.88 |
| Forward PE | -11.34 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 48 |
| Volume | 377,412 |
| Avg. Volume (20D) | 794,985 |
| Open | 47.88 |
| Previous Close | 47.87 |
| Day's Range | 47.84 - 47.90 |
| 52-Week Range | 11.56 - 48.27 |
| Beta | 2.30 |
| Ex-Dividend Date | n/a |
About TRML
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TRML
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TRML stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+57.85%
Tourmaline shares are trading higher after the com...
Unlock content with
Pro Subscription
4 months ago
-2.59%
TRML stock has given up its prior loss. Tourmaline Bio shares were trading lower. The company announced topline results from its ongoing Phase 2 TRANQUILITY trial.
3 weeks ago · seekingalpha.com
Wall Street Breakfast Podcast: Nebius Rockets On $17B Microsoft DealNebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentially expanding to $19.4B. Novartis acquires Tourmaline Bio for $1.4B in cash, a 59% premium, highligh...
